Multiple myeloma targeted drug Panobinostat

Panobinostat (Panobinostat) is an innovative drug for the targeted treatment of multiple myeloma (Multiple Myeloma, MM). As a histone deacetylase inhibitor, panobinostat has a unique mechanism of action by regulating gene expression, allowing it to show significant efficacy in patients with multiple myeloma.

Its mechanism of action mainly affects chromatin structure by inhibiting histone deacetylase, thereby regulating gene expression. Multiple myeloma is a leukemia disease caused by abnormal proliferation of plasma cells in the bone marrow. Panobinostat blocks the growth of tumor cells by inhibiting the proliferation and survival of abnormal cells.

Pabinostat is often used as part of a combination treatment regimen with other anticancer drugs such as prednisone and rituximab. Clinical trial results show that the use of panobinostat significantly improves survival in patients with multiple myeloma whose disease has progressed despite multiple treatments.

What is particularly noteworthy is that panobinostat has also shown excellent efficacy in some refractory cases. For those patients with more severe conditions who have experienced multiple rounds of treatment, panobinostat provides them with a new treatment approach and brings more hope to this troublesome disease.

However, the application of panobinostat is also associated with some adverse reactions, including hematological toxicity, cardiotoxicity, etc. Therefore, when using panobinostat, doctors need to carefully evaluate the patient's overall health and perform regular monitoring to ensure optimal treatment results.

Panobinostat is not currently on the market in China, so patients cannot purchase it domestically and need to purchase panobinostat through overseas channels. There are only panobinostat original drugs available abroad, mainly the European version of the Swiss Novartis original drug, which is expensive, as high as more than 40,000 yuan.